Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Wednesday, 28 November 2018, 11:02 HKT/SGT
Share:
    

Source: Novotech
Novotech CRO Announces 41 Clinical Staff and 81 Projects in South Korea

SYDNEY, Nov 28, 2018 - (ACN Newswire) - Asia-Pacific specialist CRO Novotech announced today that clinical staff numbers in its Seoul, South Korea centre are now at 41, with 81 clinical research projects now completed. The Novotech South Korea success is largely fueled by demand for a regional CRO with international accreditation and reputation, combined with local knowledge, partnerships and expertise.

Novotech now has 10 strategic collaborations with hospitals and research institutions in the region, and 11 offices across the Asia-Pacific region. South Korea is home to 49 million people of which 83.2% reside in urban centres. The average timeline for regulatory and IRB approval is 4-5 months.

Novotech's capabilities in South Korea are further supported by powerful partnerships with leading hospitals and medical facilities including:

The Asan Medical Centre - the largest medical institution in Korea with a total of 2,704 beds occupying about 85,000 square meters. On an average day the hospital has 11,862 outpatients, 2,557 inpatients, and 309 emergency patients, and performs about 63,791 highly sophisticated surgeries per year.

SCI-Consortium (SCIC) - a network of clinical trial centres comprising four of South Korea's leading hospitals: Yonsei University Health System (Severance Hospital and Gangnam Severance Hospital), The Catholic University of Korea St Mary's Hospital and Inha University Hospital. The network provides clinical trial access to over 1,500 investigators, almost 6,000 hospital beds and more than seven million patients per year.

One of the SCIC's key strengths is its clinical trial data system with more than ten million de-identified records. Its vast database provides easy identification of potential eligible patients, allowing much faster clinical trial recruitment. At present, the SCIC has over 30,000 active patients enrolled in clinical studies.

Novotech CEO Dr John Moller said Novotech has dedicated clinical experts within our South Korean hospital and research facilities partners to support and prioritise rapid clinical processes for Novotech biopharma clients.

He said there are many compelling reasons to consider South Korea for clinical research:
- Large patient population
- Strong and efficient regulatory environment
- Increasing use of English among the population
- World-class technological infrastructure
- Few competing trials
- Highly qualified and educated medical professionals
- Low operational costs

"Our partnership relationships enable a more comprehensive understanding of local regulatory changes, access to leading PIs, strong site connections, and productive patient populations to deliver success for our clients within timelines and budgets," Dr Moller said.

"The Novotech team is well positioned across the region to access the more than 1.4 billion people living in urban areas, which is a key factor in the decision by sponsors to include the Asia-Pacific in their global studies."

About Novotech - https://novotech-cro.com/welcome
Established in 1996 with headquarters in Sydney, Novotech is internationally recognized as the leading regional full-service contract research organization (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region.

Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. Novotech also has worldwide reach through the company's network of strategic partners.

For RFP enquiries: Please fill out the form available at www.novotech-cro.com/contact-us-0

For Media enquiries: [email protected]
Susan Fitzpatrick-Napier, AU: +61 2 8218 2144
USA: +1 415 951 3228, ASIA: +65 3159 3427



Nov 28, 2018 11:02 HKT/SGT
Topic: Press release summary
Sectors: HealthCare
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2019 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Novotech
July 11, 2019 11:00 HKT/SGT
Novotech CRO partners Skin Research Institute of Singapore (SRIS) for Skin Disorder Research
May 31, 2019 07:00 HKT/SGT
Novotech Awarded Asia-Pacific Biotech CRO of the Year - Announced at ASCO
Apr 18, 2019 04:00 HKT/SGT
Novotech CRO strengthens South Korean Clinical Capabilities, partners with 2 Major Hospitals
Mar 25, 2019 18:00 HKT/SGT
Novotech CNS USA Appoints Dr Robert Malone to its Washington, DC BioDesk
Dec 17, 2018 08:00 HKT/SGT
Novotech CRO Launches Largest Oracle Trial Management and Monitoring Cloud Service Implementation in Asia-Pacific
Oct 19, 2018 07:00 HKT/SGT
Novotech and CNS deal expands CRO services for Biopharma Clients across Asia-Pacific
Aug 23, 2018 13:00 HKT/SGT
Novotech the Asia-Pacific CRO named Top 10 CRO
Aug 9, 2018 13:00 HKT/SGT
Sponsors Recommend Novotech for CRO Leadership Award
July 19, 2018 06:00 HKT/SGT
Novotech Partners with Asian Eye Institute for Accelerated Ophthalmic Drug and Devices Clinical Trials
June 28, 2018 06:00 HKT/SGT
Novotech at DIA18 announces Asia Partnerships on Target to Reach 1.4 Bil Patients
More news >>
 News Alerts
Copyright © 2019 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: